Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the identified cause of coronavirus disease 2019 (COVID-19), continues unabated. This fact, coupled with recurrence of COVID-19 in areas where it had been controlled, highlights the critical need for a safe and effective vaccine to prevent and mitigate this novel virus. The spike protein of SARS-CoV-2 is important in its lifecycle as well as in the development of immunity after human infection. This has prompted the selection of this antigen as a focus in developing COVID-19 vaccines. This article provides (1) a summary of the host immune responses to SARS-CoV-2 infection, (2) the vaccine platforms being used with COVID-19 vaccine candidates undergoing, or about to undergo, Phase III clinical trial testing, and (3) an overview of the key criteria necessary for COVID-19 vaccine efficacy and safety. In addition, the unique concept of vaccine-enhanced disease will be discussed. [Pediatr Ann. 2020;49(12):e532–e536.]
- 1.World Health Organization. Draft landscape of COVID-19 candidate vaccines. Accessed November 16, 2020. www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines Google Scholar
- 2.Pfizer. Our progress in developing a potential COVID-19 vaccine. Accessed November 16, 2020. www.pfizer.com/science/coronavirus/vaccine Google Scholar
- 3.Zhou P, Yang X-L, Wang XG, A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270–273.
10.1038/s41586-020-2012-7 PMID:32015507 Crossref Medline, Google Scholar - 4.Long QX, Liu B-Z, Deng H-J, Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat Med. 2020; 26(6):845–848.
10.1038/s41591-020-0897-1 PMID:32350462 Crossref Medline, Google Scholar - 5.Grifoni A, Weiskopf D, Ramirez SI, Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020; 181(7):1489–1501.e15.
10.1016/j.cell.2020.05.015 PMID:32473127 Crossref Medline, Google Scholar - 6.Ibarrondo FJ, Fulcher JA, Goodman-Meza D, Rapid decay of anti-SARS-COV-2 antibodies in persons with mild COVID 19. N Engl J Med. 2020; 383(11):1085–1087.
10.1056/NEJMc2025179 PMID:32706954 Crossref Medline, Google Scholar - 7.Iyer AS, Jones FK, Nodoushani A, Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients. Sci Immunol. 2020; 5(52):eabe0367.
10.1126/sciimmunol.abe0367 PMID:33033172 Crossref Medline, Google Scholar - 8.Callow KA, Parry HF, Sergeant M, Tyrrell DA. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990; 105(2):435–446.
10.1017/S0950268800048019 PMID:2170159 Crossref Medline, Google Scholar - 9.Edridge AWD, Kaczorowska J, Hoste ACR, Seasonal coronavirus protective immunity is short lasting [published online ahead of print September 14, 2020]. Nat Med.
10.1038/s41591-020-1083-1 PMID:32929268 Crossref Medline, Google Scholar - 10.To KK-W, Hung IF-N, Ip JD, COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing [published online ahead of print August 25, 2020]. Clin Infect Dis.
10.1093/cid/ciaa1275 PMID:32840608 Crossref Medline, Google Scholar - 11.Lin JT, Zhang JS, Su N, Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007; 12(7):1107–1113. PMID:
18018769 Medline, Google Scholar - 12.Martin JE, Louder MK, Holman LA, VRC 301 Study Team. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase I clinical trial. Vaccine. 2008; 26(50):6338–6343.
10.1016/j.vaccine.2008.09.026 PMID:18824060 Crossref Medline, Google Scholar - 13.Scudellari M. Coronavirus piece by piece. Nature. 2020; 581:252–255.
10.1038/d41586-020-01444-z PMID:32415276 Crossref Medline, Google Scholar - 14.US Department of Health & Human Services. Fact sheet: explaining Operation Warp Speed. Accessed November 16, 2020. www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html Google Scholar
- 15.Slaoui M, Hepburn M. Developing safe and effective COVID vaccines-Operation Warp Speed's strategy and approach. N Engl J Med. 2020; 383(18):1701–1703.
10.1056/NEJMp2027405 PMID:32846056 Crossref Medline, Google Scholar - 16.Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020; 586(7830):516–527.
10.1038/s41586-020-2798-3 PMID:32967006 Crossref Medline, Google Scholar - 17. ClinicalTrials.gov. A study to evaluate efficacy, safety, and immunogenicity of mRNA-1273 vaccine in adults aged 18 years and older to prevent COVID-19. Accessed November 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04470427 Google Scholar
- 18.Herman AO. COVID-19: Vaccine's efficacy near 95%. NEJM J Watch. Accessed November 20, 2020. https://www.jwatch.org/fw117238/2020/11/16/covid-19-vaccines-efficacy-near-95-1m-pediatric-cases Google Scholar
- 19. ClincalTrials.gov. Study to describe the safety, tolerability, immunogenicity, and efficacy of RNA vaccine candidates against COVID-19 in healthy individuals. Accessed November 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04368728 Google Scholar
- 20.Young K. COVID-19: Pfizer vaccine efficacy/masking trial/at-home test/guidelines onBamlanivimab. Accessed November 30, 2020. https://www.jwatch.org/fw117248/2020/11/18/covid-19-pfizer-vaccine-efficacy-masking-trial-home-test Google Scholar
- 21. ClincalTrials.gov. Phase III double-blind, placebo-controlled study of AZD1222 for the prevention of COVID-19 in adults. Accessed November 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04516746 Google Scholar
- 22. ClinicalTrials.gov. A study of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adult participants (ENSEMBLE). Accessed November 16, 2020. https://clinicaltrials.gov/ct2/show/NCT04505722 Google Scholar
- 23.Bangaru S, Ozorowski G, Turner HL, Structural analysis of a full-length SARS-COV-2 spike protein from an advanced vaccine candidate [published online ahead of print October 20, 2020]. Science.
10.1126/science.abe1502 PMID:33082295 Crossref Medline, Google Scholar - 24.Bengtsson KL, Song H, Stertman L, Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola/Makona virus glycoprotein (GP) nanoparticle vaccine in mice. Vaccine. 2016; 34(16):1927–1935.
10.1016/j.vaccine.2016.02.033 PMID:26921779 Crossref Medline, Google Scholar - 25.Keech C, Albert I, Cho A, Phase 1–2 trial of a SARS-COV-2 recombinant spike protein nanoparticle vaccine [published online ahead of print September 2, 2020]. N Engl J Med.
10.1056/NEJMMoa2026920 PMID:32877576 Crossref Medline, Google Scholar - 26.US Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19. Guidance for industry. Accessed November 16, 2020. www.fda.gov/media/139638/download Google Scholar
- 27.Graham BS. Rapid COVID-19 vaccine development. Science. 2020; 368(6494):945–946.
10.1126/science.abb8923 PMID:32385100 Crossref Medline, Google Scholar
